in Vitro and in Vivo the C-8 Atom of Deoxyguanosine-Acetylbenzidine to DNA at N Covalent Binding of Benzidine and Updated Version
C. N. Martin,F. Beland,R. Roth,F. Kadlubar
Abstract:Benzidine, a human urinary bladder carcinogen, induces hepatic tumors in mice and rats. In this study, [3H]benzidine was administered in drinking water to mice for 1 week, and the covalent binding of the carcinogen to hepatic DMA was then determined. A single carcinogen:DNA adduci was detected which decreased in concentration by —50% at 1 day after treatment and then remained at a nearly constant level for at least 7 days. Injection of radiolabeled benzidine or A/-acetylbenzidine into rats also resulted in a single carcinogen:DNA adduct that was chromatographically identical to that obtained in mouse liver. While administration of benzidine and A/-acetylbenzidine resulted in high levels of the adduct in rat hepatic DNA, injection of A/,/V'-[r/ng-14C]diacetylbenzidine did not give detectable binding (<0.3 residue/mg DNA). The same carcinogen:DNA adduct found in rat and mouse liver was prepared synthetically by: (a) hydrolysis of calf thy mus DNA reacted with A/-hydroxy-A/'-acetylbenzidine at pH 5; and (b) reaction of A/-acetoxy-/V,/V'-diacetylbenzidine with deoxyguanosine and subsequent selective deacetylation of the product with methanolic ammonia. The in vitro and in vivo products were found to have identical high-pressure liquid chromatography retention times and to exhibit similar pH-dependent solvent partitioning characteristics. Mass and nuclear magnetic resonance spectral data of the synthetic products established the structure of the hepatic adduct as AMdeoxyguanosin-8-yl)-/V'-acetylbenzidine. The structural isomer, A/-(deoxyguanosin-8-yl)-/V-acetylbenzidine, was synthesized by treatment of /V-(deoxyguanosin-8-yl)-A/,/V'-diacetylbenzidine (the intermediate in o) with carboxylesterase and was shown to be chromatographically distinct from the in vivo adduct. Similarly, the nonacetylated derivative, AMdeoxyguanosin-8-yl)benzidine, was synthesized by carboxylesterase treatment of A/-(deoxyguanosin-8-yl)-A/'-acetylbenzidine and was shown not to occur in rat and mouse liver DNA. These data indicate that the metabolic activation of benzidine to an ultimate carcinogen in rats and mice does not involve W-hydroxybenzidine or sulfotransferase-catalyzed activation of A/-hydroxy-A/,A/'-diacetylbenzidine. The remaining pathways for metabolic conversion of benzidine to an ultimate carcino genic species are discussed in relation to liver and urinary bladder carcinogenesis. INTRODUCTION BZ3 has been identified as one of the aromatic amines responsible for elevated bladder tumor incidences in industrial workers (8, 27) and has been shown to induce tumors in a variety of experimental animals (12, 39). Early studies on the metabolism of BZ have identified many urinary detoxification products; however, little is known about the in vivo metabolic activation of this compound. For other carcinogenic aromatic amines, metabolic activation pathways have been described (reviewed in Refs. 21, 23, and 30), and the structures of several major carcinogen:DNA adducts have been elucidated. For example, A/-hydroxy-2-naphthylamine is known to bind to guanine at the C-8 and A/2atoms and to adenine at the A/6atom (16, 20); /V-hydroxy-1-naphthylamine binds at the O6 atom of guanine (19); 2-acetylaminofluorene binds at the C-8 and A/2 atoms of guanine (for references, see Refs. 21, 23, and 30); and A/-methyl-4-aminoazobenzene binds at the C-8 and N2 atoms of guanine and at the N6 atom of adenine (5, 25, 42). Similar information was not available on metabolic pathways for BZ leading to DNA binding in vivo. This study was under taken to gain a better understanding of the relationships be tween arylamine structure, reactivity, biological persistence of DNA adducts, and carcinogenicity. Morton ef al. (33) showed that BZ can be metabolized in vitro by A/,A/'-diacetylation and subsequent A/-hydroxylation to N-OH-DABZ. This compound could then be activated to a DNAreactive species by either sulfotransferase (32) or A/,O-acyltransferase (6, 33). Recently, carcinogenicity data for several BZ derivatives in the rat have been reported (34) which dem onstrate that BZ and N-OH-DABZ are clearly more potent than is DABZ. Martin and Ekers (28) presented data suggesting that the major in vivo DNA adduct formed by BZ involved binding to deoxyguanosine. They also suggested that this adduct could be generated by the reaction of presumed W-benzoyloxybenzidine with either DNA or deoxyguanosine. These results im plied that acetylation was not involved in in vivo metabolic activation; however, no structural characterization of the ad duct was attempted. Further investigation of the reaction between presumed A/-benzoyloxybenzidine and DNA revealed that the product was dissimilar to that induced by BZ in vivo. Although the retention times on reversed-phase HPLC were identical, solvent parti1For simplicity, throughout this manuscript the nitrogen atom of benzidine through which binding to deoxyguanosine occurs has been designated as the nonprime nitrogen. 2 Visiting Scientist. United States Food and Drug Administration. To whom requests for reprints should be addressed, at Cancer Research Unit. University of York. York Y01 5DD, United Kingdom. Received December 4, 1981; accepted April 8, 1982. 3 The abbreviations used are: BZ, benzidine; N-OH-DABZ, W-hydroxy-N,Wdiacetylbenzidine; DABZ, N.N'-diacetylbenzidine; HPLC. high-pressure liquid chromatography; N-Weoxyguanosin-S-yD-W'-ABZ, AMdeoxyguanosin-S-yD-Wacetylbenzidine; DMSO, dimethyl sulfoxide; ABZ, N-acetylbenzidine; TLC, thinlayer chromatography; N-OH-N'-ABZ, N-hydroxy-W-acetylbenzidine; NMR, nu clear magnetic resonance; N-OAc-DABZ, N-acetoxy-A/,W'-diacetylbenzidine; N-(deoxyguanosin-8-yl)DABZ, W-<deoxyguanosin-8-yl)-N,A/'-diacetylbenzidine; W-(deoxyguanosin-8-yl)BZ. N-(deoxyguanosin-8-yl)benzidine; N-OH-BZ, N-hydroxybenzidine; W-benzoyloxy-BZ, W-benzoyloxybenzidine. 2678 CANCER RESEARCH VOL. 42 American Association for Cancer Research Copyright © 1982 on February 23, 2013 cancerres.aacrjournals.org Downloaded from DNA Adduct Formation from BZ and ABZ tioning characteristics of the 2 products were different; the in vitro product was completely extractable into hexane while the in vivo adduct was not extractable by this solvent.4 In the present report, new approaches were developed to synthesize 4 possible C-8 deoxyguanosine adducts. One major DMA adduct was detected in both mouse and rat liver and, through comparison to the synthetic products, was identified as N-(deoxyguanosin-8-yl)-N'-ABZ. The possible pathways of BZ metabolism which lead to this adduct are discussed. MATERIALS AND METHODS Animals. Male Sprague-Dawley rats (9 to 23 weeks old, 250 to 350 g) from our breeding colony were fed a pelleted basal diet (No. 5755C; Ralston Purina, St. Louis, Mo.) ad libitum. C57BL/6 x BALB/c F( mice were from our breeding colony and were treated at 6 weeks of age. Chemicals. The following materials were purchased from the com mercial sources indicated: calf thymus DNA (type I), deoxyguanosine, DNase I (type DN-CI), alkaline phosphatase (type III-S), acid phosphatase (type 1), carboxylesterase (types I and II), and bis(2hydroxyethyl)iminotris(hydroxymethyl)methane and Tris bases from Sigma Chemical Co., St. Louis, Mo.; Bio-Gel HTP hydroxylapatite (DNA grade) from Bio-Rad Laboratories, Richmond, Calif.; nuclease P, (grade B) from Calbiochem-Behring Corp., San Diego, Calif.; Silica Gel 60 analytical thin-layer plates from E. Merck, Darmstadt, Germany; tetrahydrofuran (reagent grade containing stabilizer) from Taylor Chemical Co., St. Louis, Mo.; DMSO-d6 and D2O from Merck, Sharp, and Dohme, Ltd., Montreal, Quebec, Canada; BZ, [ring-"C]BZ (14.1 mCi/mmol), [ring-14C]ABZ (17.9 mCi/mmol), and [r/ng-"'C]DABZ (17.1 mCi/mmol) from Dr. William P. Duncan, Midwest Research Institute. m-Chloroperoxybenzoic acid was purchased from Aldrich Chemical Co., Milwaukee, Wis., and purified according to the method of Fieser and Fieser (10). rRNA was prepared from rat liver (15). Synthesis of [acety/-3H]ABZ. A mixture of 1.39 mmol 4-nitro-4'aminobiphenyl (14) and 2.0 mmol [3H]acetic anhydride (180 mCi) in 15 ml benzene was refluxed for 15 min and then concentrated under reduced pressure. The precipitate obtained was dissolved in 100 ml of ethanol and hydrogenated over 100 mg of 5% palladium on carbon at 40 psi for 12 hr at room temperature. The reaction was filtered, and the solvent was removed under reduced pressure. The residue was then dissolved in hot ethanol and acidified with hydrochloric acid. The resulting hydrochloride salt was washed with cold ethanol, resuspended in chloroform, and treated with dilute sodium hydroxide to obtain the free base. Recrystallization from tetrahydrofuran:hexane and then ethanol:water afforded [acefy/-3H]ABZ (45 mCi/mmol) in 68% yield which was identical in all respects to an authentic standard. TLC analysis on silica gel with hexaneiacetone (1:1) and tetrahydrofuran as solvent systems (R( 0.18 and 0.50, respectively) indicated a radiochemical purity of 99%. Synthesis of [2,2'-3H]BZ. A solution of 341 fimol of 2,2'-dibromobenzidine (11) and 11 mg of 5% palladium on charcoal in 2.2 ml of 355 mM ethanolic sodium hydroxide was stirred under 170 /imol of tritium gas (10 Ci) for 15.5 hr and then with hydrogen gas for 4 hr. The reaction mixture was filtered, and the solvent was removed under reduced pressure. The product was diluted with unlabeled BZ and recrystallized from benzene to yield [2,2'-3H]BZ (115 mCi/mmol). TLC analysis on silica gel with 2 solvent systems, hexane:acetone (4:6) and tetrahydrofuran (Rf 0.37 and 0.54, respectively), indicated a radiochemical purity £99%. Synthesis of [2,2'-3H>N-OH-N'ABZ. A suspension of 4.88 mmol [2,2'-3H]BZ (56.6 mCi/mmol) in 8 ml diethyl ether was stirred at room temperature while adding a total of 500 nil acetic anhydride in 50-/il aliquots over 1 hr (45). The volatile components were removed under 4 C. N. Martin and S. F. Ekers. unpublished studies. reduced pressure, a